gained popularity among clinical data partners worldwide. DRN uses the same data structure, called the Common Data Model (CDM), to run the same analysis program for participating organizations and then combine the results summarized over the network to provide results across the network. Data is stored in a CDM that achieves both syntactic and semantic interoperability, enabling consistent queries to be applied to databases around the world [2] . OHDSI (http://www.ohdsi.org) (Figure 1 ) is an organization of international collaborators with more than 120 researchers committed to making this clinical big data analysis a reality. OHDSI has transformed more than 680 million patient data from 56 databases in 12 countries into the Observational Medical Outcomes Partnership (OMOP) CDM format. It carried out a monumental study on chronic diseases prescription patterns using 250 million patient data items from four countries in the network [3] . In Korea, 4.6 million patient data from two university hospitals have been converted to CDM v5. In addition, seven Korean university hospitals and one Korean government agency joined OHDSI to convert their data into CDM. By the end of 2017, over 20 million patient data are expected to be available in CDM v5 format in Korea. The advantage of Electronic Medical Record (EMR) data for observational study data is that there is a detailed timestamp for each activity as well as laboratory test results and outcomes [4] . However, events that occur outside the hospital cannot be captured in the hospital EMR data. Conversely, insurance claim data does not include laboratory test results or detailed timestamps, but there are virtually all diagnoses, prescriptions, and procedures that have occurred in the country. Fortunately, one million randomly drawn Korean patient data from the past 9 years of claim data have been converted to OMOP CDM v5, and the size of the conversion is likely to expand to the entire Korean population within a few years.
By providing all of their work products as open source, OHDSI has lowered the technical barriers required for participation in a DRN. With more and more data partners participating in the OHDSI network, it is expected that everyone, including students, researchers, and developers from hospitals, governments, pharmaceutical companies, and related industries seeking medical evidence, knowledge, or even artificial intelligence algorithms, will benefit from the network with unprecedentedly low cost and effort in a timely manner. However, differences in data structures and coding system between or within countries are still major barriers to being a data partner in a DRN. For Korea, we had to map local codes for diagnoses, drugs, procedures, and laboratory tests into the OMOP standard vocabulary. As there are hundreds of thousands of local codes, mapping them all into OMOP vocabulary requires huge amounts of effort, time, and financial expense. One coordination center for code mapping for each country is strongly recommended because the code mapping process requires huge and continuous efforts together with nationwide consensus. DRNs will enable researchers to access a network of billions of patients to generate evidence about all aspects of healthcare. This collaborative analysis of clinical big data across the world will lead to medical innovation along with the fourth industrial revolution [5] . In conclusion, clinical big data analysis using DRNs will serve as a key means to improve health by empowering a community to collaboratively generate evidence that can be used to promote better health decisions and better care. Patients and clinicians and all other decision-makers around the world are expected to be able to use DRN tools and evidence every day.
